Protein kinase B

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

Retrieved on: 
Monday, March 25, 2024
Shift, Protein kinase B, Cardiology, Stroke, Health, Myocardial infarction, SGLT1, Chronic kidney disease, CKD, Risk, Theatre, Endothelium, Inflammation, Knowledge, SGLT2, Diabetes, HF, University of Colorado, Vessel, University of Michigan, Inhibitor, University, Coagulation, Protein, GDMT, Heart failure, American College, Type 2 diabetes, Vasodilation, Food, Hospital, Pharmaceutical industry

In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.

Key Points: 
  • In a post-hoc analysis of data from the 10,584 patients in the SCORED Phase 3 clinical trial, 213 all-cause stroke events occurred, including 29 (13.6%) fatal events.
  • Sotagliflozin reduced the risk of all-cause stroke by 34%, with 1.2 events per 100 patient-years in the sotagliflozin group and 1.8 events per 100 patient-years in the placebo group.
  • Similarly, sotagliflozin reduced the risk of ischemic stroke by 32%, with 0.8 events per 100 patient-years in the sotagliflozin group and 1.2 events per 100 patient-years in the placebo group.
  • Candidate, University of Michigan, Ann Arbor, Michigan
    Study researchers found that sotagliflozin inhibits platelet activation through simultaneously targeting SGLT1 and SGLT2.

Atherosclerosis, Vascular Injury, and the Hunt for Drug Targets: Pusan National University and Korean Researchers' New Findings

Retrieved on: 
Friday, February 3, 2023
Membrane protein, VSMC, Artery, Neointima, Biology, NIH, Cardiac arrest, Canadian International Council, Stent, GSE, Research, Stenosis, Protein kinase B, Cell proliferation, Death, Stroke, Gene, Gene Expression Omnibus, PCK2, International Journal of Biological Sciences, Disease, Dick's Picks Volume 18, Pusan National University, Pharmaceutical industry, Medical imaging, Vaccine, Atherosclerosis

And for better therapies, we need a better understanding of the process that leads to NIH, VSMC proliferation, and vascular injury.

Key Points: 
  • And for better therapies, we need a better understanding of the process that leads to NIH, VSMC proliferation, and vascular injury.
  • A group of researchers from Korea, led by Professor Yun Hak Kim of Pusan National University, set out to find answers.
  • It is via these pathways that PCK2 and its gene regulate VSMC proliferation after vascular injury, the team reported.
  • And given the findings of our study, we believe this enzyme can also be targeted to prevent arterial re-stenosis after stent placement and improve outcomes of vascular injury treatment."

Scallop-derived Plasmalogens Enhance Memory and Learning in Mice: the Mechanism Elucidated

Retrieved on: 
Tuesday, September 6, 2022
Research, Mental Health, Fitness & Nutrition, Other Natural Resources, Biotechnology, University, Health, Natural Resources, Science, Education, Oral administration, Morris water navigation task, Higashi-ku, Plasmalogen, Dis, Research, Neuron, Memorial Day, Brain, Chicken, Impact, Developmental Biology (journal), Memory, DHA, Heart, Mouse, Maintenance, Protein kinase B, Phospholipid, Learning, Kyushu University, Neurogenesis, Trial, Disease, Animal, Randomness, ERK, Frontiers Media, BDNF, Dietary supplement, Pharmaceutical industry, Patient

Of particular note is that scallop-derived plasmalogens abundantly contain DHA-rich plasmalogens, thereby having higher functionality.

Key Points: 
  • Of particular note is that scallop-derived plasmalogens abundantly contain DHA-rich plasmalogens, thereby having higher functionality.
  • Key findings are as follows:
    Oral administration of scallop-derived plasmalogens increased hippocampal plasmalogens and thus enhanced memory and learning in mice, which was proved by the Morris Water Maze Test (a test of spatial learning) and the Novel Object Recognition Test (a test of recognition memory).
  • Reduction of hippocampal plasmalogens promoted learning and memory loss along with a decrease in memory-related gene expression.
  • This study has elucidated the mechanism underlying the effect of scallop-derived plasmalogens on memory and learning.

Marc Jacobs Fragrances Partners With The Center and Akt on TikTok to Support the LGBTQIA+ Community

Retrieved on: 
Friday, June 3, 2022
Luxury, Other Retail, LGBTQ+, Specialty, Philanthropy, Fashion, Fund Raising, Consumer, Other Philanthropy, Retail, Jewellery, Jacobs, Time, RAF kinase, Beauty, LinkedIn, Ageing, Partnership, Awareness, Organization, Center, Ladyfag, Multimedia, The Center, Skin, COTY, Coty, Homelessness, Risk, Employment, Health, NYSE, Lesbian, Gay, Bisexual & Transgender Community Center, Wrist, Freedom, AIDS, Culture, Transgender, Family, Instagram, TikTok, Organic, London Pride, Education, Protein kinase B, Safety, Tourism, Perfume, Pride

The brand will support and drive awareness for The Center and akt through Pride-focused TikTok campaigns in both countries.

Key Points: 
  • The brand will support and drive awareness for The Center and akt through Pride-focused TikTok campaigns in both countries.
  • In the UK, TikTok creator partners will enable in-app donations for akt beginning July 2nd to coincide with London Pride.
  • This Pride marks a second year of Marc Jacobs Fragrances support for The Center and the launch of an ongoing partnership with akt.
  • Marc Jacobs Fragrances has also committed to continuing support for both non-profit organizations in June 2023.

Triple-Negative Breast Cancer Disease Market Analysis Report 2021-2027 - Keytruda will Overtake Tecentriq in the TNBC Market - ResearchAndMarkets.com

Retrieved on: 
Friday, January 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Growth, Patient, Triple-negative breast cancer, Breast cancer, PTEN, HER2, Roche, Probability, PARP, Oncology Drug Advisory Committee, Immunotherapy, CXCR4, Patent, Pembrolizumab, Talazoparib, Cancer Drugs Fund, TNBC, Biomarker, Hypersensitivity, Chugai Pharmaceutical Co., PIK3CA, Fast Track, Paclitaxel, Phase, Protein kinase B, FDA, Bevacizumab, Pharmaceutical industry, Atezolizumab, Sacituzumab govitecan, EU

The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.

Key Points: 
  • The publisher estimates that in 2018, there were 2.1 million incident cases and 8.6 million five-year prevalent cases of breast cancer worldwide.
  • By 2027, incident and five-year prevalent cases of breast cancer are expected to increase to 2.3 million and 9.3 million cases, respectively.
  • The market for TNBC is also becoming increasingly segmented by biomarker status, creating fierce competition among both approved and pipeline therapies for small patient populations.
  • Breast cancer drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

SynDevRx To Present Pre-Clinical Combination Data of Evexomostat (SDX-7320) with Capivasertib (AZD-5363) During The 2021 San Antonio Breast Cancer Symposium

Retrieved on: 
Wednesday, December 8, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Research, Hormone, Hyperglycemia, Toxicity, Exercise, Prediabetes, Growth factor, Hypoxia, Diet, Oncology, Leptin, Cancer, PI3K, Hyperinsulinemia, Adiponectin, Patient, Protein kinase B, Breast cancer, Diabetes, Glycated hemoglobin, Lipid, Obesity, Trial of the century, Blood, Angiogenesis, ER, METAP2, Poster, Insulin, Breast, American Association of Clinical Endocrinologists, Pharmaceutical industry, SDX-7320, SynDevRx, Inc., SDX-7320, SYNDEVRX, INC.

SynDevRx will be presenting data based on a series of experiments that investigated the impact of evexomostat (SDX-732) on Akt treatment-induced hyperglycemia, as well as the anti-tumor effects of evexomostat when combined with capivasertib.

Key Points: 
  • SynDevRx will be presenting data based on a series of experiments that investigated the impact of evexomostat (SDX-732) on Akt treatment-induced hyperglycemia, as well as the anti-tumor effects of evexomostat when combined with capivasertib.
  • Mechanistically, data showing changes in the expression of a number of key hypoxia and innate immune system gene sets will be presented.
  • Evexomostat (SDX-7320) is being developed for use in combination with standard-of-care cancer therapies for breast and prostate cancers.
  • that is leading the research and development of treatments that address the interactions between cancer and dysregulated metabolic hormones.

Frozen Frogs May Hold Secret to Understanding Nerve Degeneration

Retrieved on: 
Friday, December 3, 2021
Student, Cell, Protein, Mathematics, Brain, Cedarville University, Sex, Biology, Bachelor, University, Embryonic development, Jordan, Cell death, Freezing, Food, Protein kinase B, Bachelor of Science, DNA, GLOBE, Bachelor of Science in Human Biology, Rotello, Pharmacy, Zoology, Lists of diseases, Apoptosis, Frostbite, Management, Vaccine, Medicine

CEDARVILLE, OHIO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Can frogs help scientists better understand how to delay nerve degeneration?

Key Points: 
  • CEDARVILLE, OHIO, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Can frogs help scientists better understand how to delay nerve degeneration?
  • This finding could also help doctors more easily track the progression of nerve degeneration in the brain.
  • They caught the frogs in the Greene County area last spring, the season when the frogs call out to one another with a loud chorus.
  • They compared the cells and frogs in various stages of freezing and thawing to find what makes freeze-tolerant frogs so unique.

Akash Launches Developer Grant Program to Support Open-Source Projects and Decentralized Web Development

Retrieved on: 
Wednesday, August 4, 2021
Defence Research and Development Organisation, Akash

Akash's Developer Grant Program is offering grants up to $100,000 in Akash Tokens (AKT) to develop open-source projects and support the evolution of the decentralized web (dWeb).

Key Points: 
  • Akash's Developer Grant Program is offering grants up to $100,000 in Akash Tokens (AKT) to develop open-source projects and support the evolution of the decentralized web (dWeb).
  • "We hope to see submissions for developer tooling, creator platforms, decentralized web services, and desktop deployment interface."
  • The Developer Grant Program has tiers ranging from $100 to $100,000 paid in AKT.
  • Award tiers include:
    Initiate Grant, $100: Will be awarded to any developer who is working to deploy and run their first application on Akash.

Akash Network's Utility Token (AKT) Pairs with Cosmos Native Coin (ATOM) Ahead of Osmosis Launch

Retrieved on: 
Thursday, June 17, 2021
Creative works, Defence Research and Development Organisation, Television shows, Akt, Protein kinase B, Akash, Osmosis, Genres

"The AKT-ATOM pair enables borderless access to AKT," said Greg Osuri, CEO of Akash Network.

Key Points: 
  • "The AKT-ATOM pair enables borderless access to AKT," said Greg Osuri, CEO of Akash Network.
  • "Users worldwide can now enjoy access to AKT, the native token of the world's first open cloud, in a permissionless and secure way."
  • Launching with 7 chains including Akash Network, Cosmos, Regent, IRIS, Sentinel, and Persistence, AKT will be the first tradable asset in the Cosmos ecosystem to be available on Osmosis upon its launch.
  • "We're excited to have Akash Network be one of the first launch partners of Osmosis," said Sunny Aggarwal, Co-founder of Osmosis.

Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, May 10, 2021
Branches of biology, Signal transduction, Biology, Oncology, PI3K/AKT/mTOR pathway, Protein kinases, Phosphoinositide 3-kinase, Protein kinase B, MTOR, Diffusion Pharmaceuticals

The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.

Key Points: 
  • The study evaluated the safety and tolerability of TSC when administered every six hours for up to 15 days, a dosing regimen previously untested in a clinical trial setting.
  • Topline results, reported in mid-February 2021, showed that all doses evaluated were well tolerated and no dose-limiting toxicities or serious adverse events were observed.
  • Diffusion intends to initiate clinical studies in the identified indications during the first quarter of 2022.\nDiffusion Pharmaceuticals Inc. is an innovative biopharmaceutical company developing novel therapies that enhance the body\xe2\x80\x99s ability to deliver oxygen to areas where it is needed most.
  • In addition to TSC, Diffusion\xe2\x80\x99s product candidate DFN-529, a novel, allosteric PI3K/Akt/mTOR Pathway inhibitor, is in early-stage development.